The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,360.00
Bid: 12,360.00
Ask: 12,364.00
Change: 242.00 (2.00%)
Spread: 4.00 (0.032%)
Open: 12,244.00
High: 12,368.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

Tue, 16th Jan 2024 09:14

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

----------

FTSE 100

----------

JPMorgan cuts Rightmove to 'underweight' (neutral) - price target 493 (585) pence

----------

Goldman Sachs raises Rightmove price target to 667 (659) pence - 'neutral'

----------

JPMorgan cuts HSBC price target to 660 (690) pence - 'neutral'

----------

JPMorgan cuts Standard Chartered price target to 820 (990) pence - 'overweight'

----------

Jefferies cuts Standard Chartered price target to 1,050 (1,100) pence - 'buy'

----------

JPMorgan cuts NatWest price target to 260 (280) pence - 'overweight'

----------

JPMorgan cuts Barclays price target to 180 (190) pence - 'overweight'

----------

Jefferies raises Berkeley price target to 4,706 (4,572) pence - 'hold'

----------

Jefferies raises Barratt Developments price target to 583 (470) pence - 'hold'

----------

Peel Hunt cuts Taylor Wimpey to 'hold' (add) - price target 145 (125) pence

----------

Jefferies raises Taylor Wimpey price target to 172 (143) pence - 'buy'

----------

JPMorgan raises Taylor Wimpey price target to 101 (96) pence - 'neutral'

----------

Citigroup raises Beazley price target to 723 (680) pence - 'buy'

----------

Citigroup cuts Prudential price target to 1130 (1350) pence - 'buy'

----------

UBS cuts Rentokil Initial price target to 375 (460) pence - 'sell'

----------

Goldman Sachs raises Auto Trader group price target to 886 (863) pence - 'buy'

----------

Barclays cuts Croda International target to 5,000 (6,300) pence - 'equal weight'

----------

Goldman Sachs raises WPP price target to 870 (849) pence - 'neutral'

----------

Goldman Sachs raises Informa price target to 1,027 (1,019) pence - 'buy'

----------

Goldman Sachs raises Relx price target to 3,795 (3,405) pence - 'buy'

----------

Goldman Sachs raises Pearson price target to 1,319 (1,225) pence - 'buy'

----------

Berenberg cuts Rolls-Royce to 'sell' (hold) - price target 240 (100) pence

----------

Bernstein raises Convatec price target to 305 (285) pence - 'outperform'

----------

Morgan Stanley raises AstraZeneca price target to 13,400 (12,900) pence - 'overweight'

----------

UBS cuts AstraZeneca to 'sell' (buy) - price target 10,700 (13,000) pence

----------

Morgan Stanley raises GSK price target to 1730 (1535) pence - 'equal-weight'

----------

UBS raises GSK to 'buy' (sell) - price target 1,860 (1,310) pence

----------

Citigroup raises St James's Place price target to 667 (660) pence - 'neutral'

----------

Citigroup raises Phoenix price target to 509 (501) pence - 'neutral'

----------

Citigroup raises M&G price target to 223 (208) pence - 'neutral'

----------

Citigroup raises Legal & General price target to 254 (232) pence - 'neutral'

----------

Citigroup raises Aviva price target to 450 (422) pence - 'neutral'

----------

Deutsche Bank cuts Diageo price target to 2,450 (2,470) pence - 'sell'

----------

Goldman Sachs raises Experian price target to 4,250 (4,000) pence - 'buy'

----------

FTSE 250

----------

RBC starts Premier Foods with 'outperform' - price target 180 pence

----------

Citigroup raises Hiscox price target to 1,084 (1,032) pence - 'neutral'

----------

RBC cuts PageGroup price target to 550 (560) pence - 'outperform'

----------

Barclays raises Spire Healthcare price target to 315 (305) pence - 'overweight'

----------

Berenberg raises Direct Line to 'buy' (hold) - price target 195 (170) pence

----------

Jefferies raises Redrow price target to 774 (635) pence - 'buy'

----------

Jefferies raises Vistry price target to 1,023 (831) pence - 'hold'

----------

Citigroup cuts Drax to 'sell' (buy) - price target 437 (474) pence

----------

Barclays cuts Johnson Matthey target to 2,030 (2,100) pence - 'equal weight'

----------

Goldman Sachs cuts ITV to 'sell' (neutral) - price target 60 (67) pence

----------

Jefferies raises Persimmon to 'buy' (hold) - price target 1,706 (1,181) pence

----------

Jefferies cuts Crest Nicholson to 'hold' (buy) - price target 234 (331) pence

----------

Jefferies raises Bellway price target to 3,301 (2,827) pence - 'buy'

----------

Jefferies cuts Moneysupermarket.com to 'hold' (buy) - price target 265 (305) pence

----------

JPMorgan raises Ashmore price target to 185 (183) pence - 'underweight'

----------

SMALL CAP

----------

Numis cuts Wise to 'hold' (buy) - price target 950 pence

----------

Morgan Stanley raises Wise price target to 1,070 (1,050) pence - 'overweight'

----------

Goldman Sachs raises Wise price target to 1,250 (1,200) pence - 'buy'

----------

Goldman Sachs raises Wise price target to 1,250 (1,200) pence - 'buy'

----------

UBS cuts Card Factory price target to 107 (109) pence - 'neutral'

----------

investec cuts Reach to 'hold' (buy) - price target 70 (100) pence

----------

Peel Hunt raises Oxford Nanopore to 'reduce' (sell) - price target 155 pence

----------

Barclays raises Synthomer price target to 416 (187) pence - 'equal weight'

----------

JPMorgan cuts Bank of Ireland to 'underweight' (neutral) - price target 8 (10.80) EUR

----------

JPMorgan cuts AIB price target to 4.80 (5.80) EUR - 'overweight'

----------

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
Today 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
Today 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.